Search This Blog

Tuesday, September 8, 2026

BEAM-302 Phase 1/2 biomarker gains in AATD, starts global pivotal cohort for potential U.S. accelerated approval

 

Beam Therapeutics posts durable BEAM-302 Phase 1/2 biomarker gains in AATD, starts global pivotal cohort for potential U.S. accelerated approval

  • Updated BEAM-302 data in AATD were presented at ERS 2026.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)